Alzinova initiates development of a stable cell line to prepare the monoclonal antibody ALZ-201 for Alzheimer's clinical trials

Unique oligomer specificityAggregation of the amyloid beta peptide in the brain is widely recognized as a main driver of Alzheimer's disease. Both ALZ-201 and ALZ-101 are novel immunotherapies that specifically target a toxic, oligomeric form of the amyloid beta peptide. Unique oligomer specificityAggregation of the amyloid beta peptide in the brain is widely recognized as a main driver of Alzheimer's disease. Both ALZ-201 and ALZ-101 are novel immunotherapies that specifically target a...

STOCKHOLM, 24/05/2022 (informazione.news - comunicati stampa - scienza e tecnologia)

Aggregation of the amyloid beta peptide in the brain is widely recognized as a main driver of Alzheimer's disease. Both ALZ-201 and ALZ-101 are novel immunotherapies that specifically target a toxic, oligomeric form of the amyloid beta peptide.

Anders Sandberg , Chief Scientific Officer at Alzinova, comments, "With its unique binding profile, ALZ-201 stands out for us as the only antibody specifically targeting toxic amyloid beta. Preventing oligomers' toxic effect on brain cells could translate into high efficacy and more favourable safety profiles, with "best-in-class" potential compared to other amyloid beta-targeting immunotherapies. By initiating this next step to develop a stable cell line to produce ALZ-201, we are furthering our commitment to utilise our unique technology to develop disease modifying therapies to help patients suffering from Alzheimer's disease."

Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/alzinova/r/alzinova-initiates-development-of-a-stable-cell-line-to-prepare-the-monoclonal-antibody-alz-201-for-,c3573445

The following files are available for download: